A Case of Development of Vitiligo Followed by TNF-alpha Antagonist Treatment for Rheumatoid Arthritis.
10.4078/jrd.2012.19.4.216
- Author:
Ran SONG
1
;
So Mi KIM
;
Sang Hoon LEE
;
Yeon Ah LEE
;
Seung Jae HONG
;
Hee Ryung CHO
;
Gou Young KIM
;
Hyung In YANG
Author Information
1. Division of Rheumatology, School of Medicine, Kyung Hee University, Seoul, Korea. happiran@paran.com
- Publication Type:Case Report
- Keywords:
Rheumatoid arthritis;
TNF-alpha antagonist;
Vitiligo
- MeSH:
Arthritis, Rheumatoid;
Biological Agents;
Female;
Hand;
Humans;
Immunoglobulin G;
Lasers, Excimer;
Receptors, Tumor Necrosis Factor;
Rheumatic Diseases;
Skin;
Spondylitis, Ankylosing;
Tacrolimus;
Tumor Necrosis Factor-alpha;
Vitiligo;
Young Adult;
Etanercept
- From:Journal of Rheumatic Diseases
2012;19(4):216-219
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
As the usage of biologics for rheumatic diseases increases, such as rheumatoid arthritis and ankylosing spondylitis, various cutaneous adverse events are also being increasingly reported. We experienced a case of development of vitiligo during a TNF-alpha antagonist therapy in a 22-year-old woman with rheumatoid arthritis. The patient was presented with vitiligo lesions on the dorsum of both hands after 1 month of treatment with etanercept. Vitiligo improved with topical tacrolimus ointment and excimer laser treatment without the discontinuation of etanercept. No clearly defined mechanism for vitiligo induced by TNF-alpha antagonist exits. However, considering that vitiligo is an autoimmune disorder, the development of this skin lesion in association with the TNF-alpha antagonist could be explained by a paradoxical induction of the autoimmune process.
